Article Text

Download PDFPDF
Evolving European guidance on the medical management of neovascular age related macular degeneration
  1. U Chakravarthy1,
  2. G Soubrane2,
  3. F Bandello3,
  4. V Chong4,
  5. C Creuzot-Garcher5,
  6. S A Dimitrakos II6,
  7. J-F Korobelnik7,
  8. M Larsen8,
  9. J Monés9,
  10. D Pauleikhoff10,
  11. C J Pournaras11,
  12. G Staurenghi12,
  13. G Virgili13,
  14. S Wolf14
  1. 1Queen’s University and Royal Victoria Hospitals, Belfast, UK
  2. 2Department of Ophthalmology, University of Créteil-Paris XII, France
  3. 3Department of Ophthalmology, University of Udine, Italy
  4. 4King’s College Hospital, University of London, UK
  5. 5Service d’Ophtalmologie, Université de Bourgogne, Dijon, France
  6. 6Department of Ophthalmology, Aristotle University of Thessaloniki, Greece
  7. 7Service d’Ophtalmologie, Hôpital Pellegrin, Bordeaux, France
  8. 8Herlev Hospital, University of Copenhagen, Denmark
  9. 9Instituto de Microcirugia Ocular de Barcelona, Spain
  10. 10St. Franziskus Hospital, Münster, Germany
  11. 11Geneva University Hospital, Switzerland
  12. 12Eye Clinic, University of Milan, Italy
  13. 13Eye Clinic, University of Florence, Italy
  14. 14University Ophthalmology Clinic, Inselspital, Bern, Switzerland
  1. Correspondence to: Gisèle Soubrane Department of Ophthalmology, University-Paris XII-Créteil, 40 Avenue de Verdun, Créteil, France 94010; gisele.soubrane{at}chicreteil.fr

Footnotes

  • Competing interests: Usha Chakravarthy has been an investigator in the VISION study and has been a paid consultant in expert advisory boards for Novartis Pharma AG and Pfizer Inc. Gisèle Soubrane has participated in multiple expert advisory boards and has been reimbursed by Eyetech Pharmaceuticals, Inc, Novartis Pharma AG, Alcon, Inc, Pfizer Inc, Genaera Corporation and Allergan, Inc for attending several conferences and for running educational programmes. Francesco Bandello has been reimbursed by Novartis Pharma AG, Alcon, Inc, and Pfizer Inc for attending several conferences. Victor Chong has been reimbursed by Novartis Pharma AG for attending several conferences, and has received funds for a member of staff and fees for consultation. Catherine Creuzot-Garcher has declared no competing interests. Stavros A Dimitrakos has been reimbursed by Novartis Pharma AG for attending a meeting. Jean-François Korobelnik is a paid consultant for Pfizer Inc and has been paid by Alcon, Inc for running educational programmes. Michael Larsen has been reimbursed by Novartis Pharma AG and Pfizer Inc for speaking at symposia and for consulting services. Jordi Monés has has participated in multiple expert advisory boards and has been reimbursed by Eyetech Pharmaceuticals, Inc, Novartis Pharma AG, Pfizer Inc, Allergan Inc, Genaera Corporation. Daniel Pauleikhoff has participated in multiple expert advisory boards and has been reimbursed by Pfizer Inc. Constantin J Pournaras has declared no competing interests. Giovanni Staurenghi has declared no competing interests. Gianni Virgili has been reimbursed by Novartis Pharma AG for attending several conferences and speaking at one conference. Sebastian Wolf has been reimbursed by Novartis Pharma AG, Pfizer Inc, and Alcon, Inc for attending several conferences, and has received research grants and consultancy fees from Novartis Pharma AG and Pfizer Inc.

View Full Text

Statistics from Altmetric.com

Footnotes

  • Competing interests: Usha Chakravarthy has been an investigator in the VISION study and has been a paid consultant in expert advisory boards for Novartis Pharma AG and Pfizer Inc. Gisèle Soubrane has participated in multiple expert advisory boards and has been reimbursed by Eyetech Pharmaceuticals, Inc, Novartis Pharma AG, Alcon, Inc, Pfizer Inc, Genaera Corporation and Allergan, Inc for attending several conferences and for running educational programmes. Francesco Bandello has been reimbursed by Novartis Pharma AG, Alcon, Inc, and Pfizer Inc for attending several conferences. Victor Chong has been reimbursed by Novartis Pharma AG for attending several conferences, and has received funds for a member of staff and fees for consultation. Catherine Creuzot-Garcher has declared no competing interests. Stavros A Dimitrakos has been reimbursed by Novartis Pharma AG for attending a meeting. Jean-François Korobelnik is a paid consultant for Pfizer Inc and has been paid by Alcon, Inc for running educational programmes. Michael Larsen has been reimbursed by Novartis Pharma AG and Pfizer Inc for speaking at symposia and for consulting services. Jordi Monés has has participated in multiple expert advisory boards and has been reimbursed by Eyetech Pharmaceuticals, Inc, Novartis Pharma AG, Pfizer Inc, Allergan Inc, Genaera Corporation. Daniel Pauleikhoff has participated in multiple expert advisory boards and has been reimbursed by Pfizer Inc. Constantin J Pournaras has declared no competing interests. Giovanni Staurenghi has declared no competing interests. Gianni Virgili has been reimbursed by Novartis Pharma AG for attending several conferences and speaking at one conference. Sebastian Wolf has been reimbursed by Novartis Pharma AG, Pfizer Inc, and Alcon, Inc for attending several conferences, and has received research grants and consultancy fees from Novartis Pharma AG and Pfizer Inc.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.